Biofrontera Inc. Common Stock (BFRI)

FairStock Score: 62/100 — STEADY

Key Financials

Strengths

• Strong Piotroski F-Score of 7/9 indicating robust financial health across profitability, leverage, and efficiency metrics
• Healthy net profit margin of 13.5% showing consistent profitability
• Revenue growth of 36.2% demonstrates strong top-line momentum

Concerns

• Altman Z-Score of -4.5 places it in the financial distress zone—elevated bankruptcy risk

AI Analysis

Biofrontera Inc. Common Stock is a micro-cap healthcare company valued at $12 million. The business generates $42 million in annual revenue with a 13.5% net margin. From a quality standpoint, Biofrontera shows solid Piotroski F-Score of 7/9 and distressed Altman Z-Score of -4.5 warrants caution. Growth dynamics show revenue growing at 36.2% and profit growth of 504.0%. Our composite FairStock Score of 62/100 reflects above-average fundamentals overall. Investors should weigh the business quality against the current price and their own margin of safety requirements.

Bull Case

Biofrontera's 36% revenue growth trajectory could accelerate as it captures additional market share in the healthcare sector. Operational leverage in the business model means incremental revenue growth could disproportionately boost bottom-line profitability.

Bear Case

Macro headwinds or sector-specific disruption could pressure margins, particularly if competitive intensity increases in the healthcare space. Regulatory changes, input cost inflation, or demand normalization represent underappreciated risks that could materially impact forward estimates.

Data from SEC filings. AI analysis is for educational purposes only — not investment advice. Scoring methodology · Disclaimer